Repligen (NASDAQ: RGEN) net income
Repligen reported a net profit of $48.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $25.5m. Its net margin was 6.6%. Earnings per share were $0.87.
Repligen's best year of the last 10 was fiscal 2022. The biggest drop was in fiscal 2023, −80.9%. It reported a loss in 1 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $48.9m | — | 6.6% | $0.87 |
| 2024 | −$25.5m | −171.7% | −4.0% | −$0.46 |
| 2023 | $35.6m | −80.9% | 5.6% | $0.75 |
| 2022 | $186.0m | +45.0% | 23.2% | $3.35 |
| 2021 | $128.3m | +114.1% | 19.1% | $2.33 |
| 2020 | $59.9m | +179.9% | 16.4% | $1.14 |
| 2019 | $21.4m | +28.8% | 7.9% | $0.44 |
| 2018 | $16.6m | −41.4% | 8.6% | $0.38 |
| 2017 | $28.4m | +142.7% | 20.1% | $0.74 |
| 2016 | $11.7m | — | 11.2% | $0.35 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Repligen net income compared with its sector
By net income for its latest fiscal year, Repligen ranks 133rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Repligen, 6.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 131st | LeMaitre Vascular | $57.7m | 23.1% |
| 132nd | Emergent Biosolutions | $52.6m | 7.1% |
| 133rd | Repligen | $48.9m | 6.6% |
| 134th | MiMedx Group | $48.6m | 11.6% |
| 135th | Conmed | $47.1m | 3.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Repligen
- How much did Repligen earn in fiscal 2025?
- Repligen reported a net profit of $48.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $25.5m.
- What are the earnings per share of Repligen?
- They were $0.87 in fiscal 2025, compared with −$0.46 in fiscal 2024.
- What is the net margin of Repligen?
- In fiscal 2025 its net profit was 6.6% of its revenue.
- What was the most profitable year for Repligen?
- Of its last 10 fiscal years, fiscal 2022, with $186.0m.
- Where does Repligen rank in its sector by net income?
- It ranks 133rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Repligen come from?
- From the annual report (Form 10-K) that Repligen files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Repligen files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Repligen: the Repligen page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.